Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Adverse events · patients with induction of remission in ulcerative colitis

Etrolizumab probably leads to lower adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Etrolizumab for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.75 [0.57, 0.99]
1 study · 124 participants
Moderate

Serious adverse events · patients with induction of remission in ulcerative colitis

Etrolizumab showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Etrolizumab for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.92 [0.36, 2.34]
2 studies · 165 participants
Low